As I've mentioned before, I'm a booster for DNA G-quadruplexes as drug targets. While telomeres might not be the best target, there are lots of potentially oncogenically relevant quadruplexes. Here is the only quadruplex-targeting antineoplastic that's made it into the clinic that I know of.
Quarfloxin, predictably, has a large aromatic surface area and a chirally disposed positive charge - perfect for targeting a groove or loop. It has shown great promise in early clinical work (it's currently in phase II) - I am rooting for the class!
- Log in to post comments
More like this
As I write this, I'm winging my way home from TAM, crammed uncomfortably—very uncomfortably—in a window seat in steerage—I mean, coach).
I had thought of simply recounting the adventures of the contingent of skeptics with whom I'm associated who did make it out to TAM to give talks at workshops and…
There are times when, as a scientist, I look at an idea and its execution and simply stand in awe. It's particularly satisfying when it's a relatively simple idea that could conceivably do a lot of good for a lot of patients. Oddly enough, whether it's because I've been out of the loop or because…
I was originally going to write about an amazing article that appeared in the NEJM today, but then, as happens all too often, something more compelling caught my eye. Unfortunately, it's compelling in exactly the wrong way. It's infuriating and saddening, all at the same time. It's also yet another…
It's known as "targeted" therapy, and it's the holy grail of cancer research these days. If you listen to its most vocal proponents, it's the path towards "personalized medicine" that improves survival with much lower toxicity, in which, instead of using the hammer that is chemotherapy, precisely…